Real-world evaluation of epidemiology, treatment environment and bone fracture risk associated with glucocorticoid-induced osteoporosis in Japan

Real-world evaluation of epidemiology, treatment environment and bone fracture risk associated with glucocorticoid-induced osteoporosis in Japan - Real-world evaluation of epidemiology, treatment environment and bone fracture risk associated with glucocorticoid-induced osteoporosis in Japan

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041498

Enrollment

40000

Registered

2020-08-22

Start date

2020-07-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glucocorticoid-induced osteoporosis (GIOP)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients newly prescribed oral GC between April 2009 and March 2019, having a total GIOP score of three or more, not considering a score by lumber bone density based on the JSBMR 2014 guideline

Exclusion criteria

Exclusion criteria: Having been diagnosed with any endocrine disease of interest which associated with reduced bone density

Design outcomes

Primary

Measure	Time frame
Longitudinal occurrence of GIOP-related fractures	—

Secondary

Measure	Time frame
Duration of oral GC, Average oral GC dose per day, Proportion of patients who received GIOP treatment, Proportion of patients undergoing regular spinal X-ray, Proportion of patients undergoing regular bone densitometry	—

Countries

Japan

Contacts

Public ContactMariko Nomoto

Creativ-Ceutical K.K. HEOR

mariko.nomoto@creativ-ceutical.com03-6717-4160

Outcome results